title: Association of immune globulin intravenous and thromboembolic adverse events.
authors.affiliation: Office of Tissues and Advanced Therapies, CBER, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Mikhail V
authors.initials: MV
authors.lastname: Ovanesov
authors.affiliation: Office of Biostatistics and Epidemiology, CBER, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Mikhail D
authors.initials: MD
authors.lastname: Menis
authors.affiliation: Office of Tissues and Advanced Therapies, CBER, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Dorothy E
authors.initials: DE
authors.lastname: Scott
authors.affiliation: Office of Biostatistics and Epidemiology, CBER, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Richard
authors.initials: R
authors.lastname: Forshee
authors.affiliation: Office of Biostatistics and Epidemiology, CBER, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Steven
authors.initials: S
authors.lastname: Anderson
authors.affiliation: Office of Tissues and Advanced Therapies, CBER, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Wilson
authors.initials: W
authors.lastname: Bryan
authors.affiliation: Office of Tissues and Advanced Therapies, CBER, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Basil
authors.initials: B
authors.lastname: Golding
mesh_terms: D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D013923:Thromboembolism / Q000097:blood / Q000139:chemically induced*
chemical_list: D016756:Immunoglobulins, Intravenous